Clinical Policy: Antithrombin III (~~ATryn,~~ Thrombate III)

Reference Number: LA.PHAR.564
Effective Date: 09.29.23
Last Review Date: ~~06.16.25~~03.30.26
Line of Business: Medicaid

Coding Implications
Revision Log

See Important Reminder **at the end of this policy for important regulatory and legal information.**

****Please note: This policy is for medical benefit****

Description

~~The following are antithrombin products requiring prior authorization:~~
~~antithrombin~~Antithrombin III~~, human~~ (Thrombate III®) ~~and~~is a human antithrombin~~, recombinant (ATryn®).~~ product.

FDA Approved Indication(s)

~~ATryn is indicated for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.~~

Thrombate III is indicated in adult and pediatric patients with hereditary antithrombin deficiency for:

- Treatment and prevention of thromboembolism
- Prevention of peri-operative and peri-partum thromboembolism

~~Limitation(s) of use: ATryn is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients.~~

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections® that ~~ATryn and~~ Thrombate III ~~are~~is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Hereditary Antithrombin Deficiency (must meet all)**:**

1. Diagnosis of hereditary antithrombin deficiency;
2. Prescribed by or in consultation with a hematologist;
~~3. Age ≥ 18 years;~~
~~4.~~1. ~~Member meets one of the following (a or b):~~
3. Request is for ~~Thrombate III for~~one of the ~~treatment~~following (a or b):
   a. Treatment or prevention of thromboembolism;
   b. ~~Request is for prevention~~Prevention of peri-operative or peri-partum thromboembolism.

Approval duration: ~~**6 months**~~

Formatted: Font: Not Italic
Formatted: Tab stops: Not at 2.44"
Formatted: Font: Not Italic
Formatted: Indent: Hanging: 0.25", Numbered + Level: 1 + Numbering Style: 1, 2, 3, … + Start at: 1 + Alignment: Left + Aligned at: 0.25" + Indent at: 0.75", Pattern: Clear

Acute thrombosis or peri-operative/peri-partum prevention: 3 months
Prevention: 12 months

B. Other diagnoses/indications (must meet 1 or 2)**:**
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255.
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53.

II. Continued Therapy

A. Hereditary Antithrombin Deficiency (must meet all)**:**

~~Member meets one of the following (a or b):~~
1. Currently receiving medication via Louisiana Healthcare Connections benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy.

Approval duration:

Acute thrombosis or peri-operative/peri-partum prevention: 3 months
Prevention: 12 months
~~6 months~~

B. Other diagnoses/indications (must meet 1 or 2)**:**
1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255.
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – LA.PMN.53.

B. Disseminated intravascular coagulation (DIC).

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
DIC: disseminated intravascular coagulation
FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives
Not applicable

Formatted: Indent: Left: 0", First line: 0.5"
Formatted: Font: Not Bold
Formatted: Font: Not Italic
Formatted: Indent: Hanging: 0.25", Numbered + Level: 1 + Numbering Style: 1, 2, 3, … + Start at: 1 + Alignment: Left + Aligned at: 0.25" + Indent at: 0.75", Pattern: Clear
Formatted: Indent: Left: 0", First line: 0.5"
Formatted: Font: Not Bold
Formatted: Font color: Auto
Formatted: Font: Bold, Font color: Auto

Appendix C: Contraindications/Boxed Warnings

- ~~Contraindication(s): known hypersensitivity to goat and goat milk proteins (*ATryn only*)~~
- ~~Boxed warning(s): none~~None reported

Formatted: Normal, Indent: First line: 0.25", No bullets or numbering

Appendix D: General Information

- In addition to the FDA-approved indications, antithrombin has been suggested for treatment of patients with DIC associated with trauma or sepsis. However, 2009 British guidelines for the diagnosis and management of DIC do not recommend antithrombin in patients with DIC without further prospective evidence in randomized controlled trials. More recent studies have not found clear benefit of antithrombin in treatment of DIC. A 2016 Cochrane review of antithrombin administration in critically ill patients concluded that there is insufficient evidence to support its use in any category of such patients, including those with sepsis and DIC. A 2022 statement from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH) on sepsis-induced coagulopathy in the management of sepsis concluded that although antithrombin is a candidate for anticoagulation, it has not proven to be effective with robust evidence, and future trials are warranted.

V. Dosage and Administration

~~Drug Name~~Indication	Dosing Regimen	Maximum Dose
~~Antithrombin III [human] (Thrombate III)~~Hereditary antithrombin deficiency	Individualize dose to achieve antithrombin level of 80% to 120% of normal human plasma. Loading dose (IV infusion): 120% - baseline % x body weight (kg) / 1.4% Adjustment (as needed, IV infusion): Target % - trough % x body weight (kg) / 1.4% Maintenance: Loading dose x 0.6 IV every 24 hours as needed	Varies per baseline and target antithrombin levels
~~Antithrombin [recombinant] (ATryn)~~	~~Treatment goal is to restore and maintain functional antithrombin activity levels between 80% - 120% (0.8 - 1.2 IU/mL) of normal.~~ ~~For surgical patients:~~ ~~*Loading dose (IV infusion):* 100% - baseline % x body weight (kg) / 2.3%~~ ~~*Maintenance (IV infusion):* 100% - baseline % x body weight (kg) / 10.2%~~ ~~For pregnant women:~~ ~~*Loading dose (IV infusion):* 100% - baseline % x body weight (kg) / 1.3%~~	~~Varies per baseline and target antithrombin levels~~

~~Drug Name~~Indication	Dosing Regimen	Maximum Dose
	~~*Maintenance (IV infusion):* 100% - baseline % x body weight (kg) / 5.4%~~ ~~Continue administration of ATryn until adequate follow-on anticoagulation has been established.~~	

VI. Product Availability

Single-dose vial: approximately 500 units

~~Drug Name~~	~~Availability~~
~~Antithrombin III [human] (Thrombate III)~~	~~Single-dose vial: approximately 500 units~~
~~Antithrombin [recombinant] (ATryn)~~	~~Single-dose vial: approximately 525 IU or 1,750 IU~~

VII. References

1. Thrombate III Prescribing Information. Research Triangle Park, NC: Grifols Therapeutics LLC; ~~October 2021~~July 2025. Available at: www.thrombate.com. Accessed ~~November 1, 2024~~October 23, 2025.
~~2. ATryn prescribing information. Framingham, MA: GTC Biotherapeutics, Inc; December 2013. Available at: https://www.fda.gov/media/75529/download?attachment. Accessed November 1, 2024.~~
~~3.~~2. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009 Apr;145(1):24-33.
~~4.~~3. Allingstrup M, Wetterslev J, Ravn FB, Møller AM, Afshari A. Antithrombin III for critically ill patients. Cochrane Database of Systematic Reviews 2016, Issue 2. Art. No.: CD005370.
~~5. 5. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286:1869.~~
~~6.~~4. Iba T, Levi M, Thachil J, et al. Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis. J Thromb Haemost. 2023;21(1):145-153.
~~7.~~5. Medical and Scientific Advisory Council (MASAC) of the National Bleeding Disorders (formerly National Hemophilia Foundation): Database of treatment guidelines. Available at: https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents. Accessed November ~~18, 2024~~24, 2025.

Formatted: Indent: Left: -0.06", Hanging: 0.31", Keep with next

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-

date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
~~J7196~~	~~Injection, antithrombin recombinant, 50 IU~~
J7197	Antithrombin III (human), per IU

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Policy created	05.01.23	08.28.23
Annual review: no significant changes; references reviewed and updated.	03.25.24	05.23.24
Annual review: no significant changes; references reviewed and updated	01.09.25	03.17.25
Annual review: no significant changes; references reviewed and updated	06.16.25	N/A, no material revisions
Annual review: Atryn was discontinued and removed from criteria; updated Thrombate III indication for pediatric extension and removed requirement for age ≥ 18 years; revised approval durations for prevention from 6 months to 12 months; references reviewed and updated.	03.30.26	

Formatted: Font color: Auto

Formatted: Font: Not Bold, No underline

Formatted: Keep with next

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy,

contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.